Alteration in the expression of cell-surface proteins is a common consequence of malignant
transformation. Natural killer (NK) cells use an array of germline-encoded activating and …

For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer
therapy, but there is still much room for improvement. Efforts continue to build better cancer …

CD20 is an important target for the treatment of B-cell malignancies, including non-Hodgkin
lymphoma as well as autoimmune disorders. B-cell depletion therapy using monoclonal …

Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies. Despite its
undeniable therapeutic value, we still do not fully understand the mechanisms of action …

Cancer immunotherapy comprises a variety of treatment approaches, incorporating the
tremendous specificity of the adaptive immune system (T cells and antibodies) as well as the …

Antibody‐dependent cellular cytotoxicity (ADCC) is a set of mechanisms that target cells
coated with IgG antibodies of the proper subclasses (IgG1 in the human) to be the prey of …

Several novel anti-CD20 monoclonal antibodies are currently in development with the aim of
improving the treatment of B cell malignancies. Mutagenesis and epitope map** studies …

In the last decade several therapeutic antibodies have been Federal Drug Administration
(FDA) and European Medicines Agency (EMEA) approved. Although their mechanisms of …

CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but
not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as …

Natural killer (NK) cells are involved in innate defenses against viruses and tumors. Their
function is finely tuned by activating and inhibitory receptors. Among the latter, killer …